Last reviewed · How we verify
FAK Inhibitor GSK2256098 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
FAK Inhibitor GSK2256098 (FAK Inhibitor GSK2256098) — Alliance for Clinical Trials in Oncology.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| FAK Inhibitor GSK2256098 TARGET | FAK Inhibitor GSK2256098 | Alliance for Clinical Trials in Oncology | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- FAK Inhibitor GSK2256098 CI watch — RSS
- FAK Inhibitor GSK2256098 CI watch — Atom
- FAK Inhibitor GSK2256098 CI watch — JSON
- FAK Inhibitor GSK2256098 alone — RSS
Cite this brief
Drug Landscape (2026). FAK Inhibitor GSK2256098 — Competitive Intelligence Brief. https://druglandscape.com/ci/fak-inhibitor-gsk2256098. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab